NASDAQ:DBVT - DBV TECHNOLOGIE/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.57 -0.29 (-3.69 %) (As of 02/18/2019 07:50 AM ET)Previous Close$7.86Today's Range$7.55 - $7.7852-Week Range$3.60 - $26.26Volume246,840 shsAverage Volume442,087 shsMarket Capitalization$449.94 millionP/E Ratio-2.25Dividend YieldN/ABeta1.91 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. Receive DBVT News and Ratings via Email Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBVT Previous Symbol CUSIPN/A Webwww.dbv-technologies.com Phone33-1-55-42-78-78Debt Debt-to-Equity Ratio0.01 Current Ratio6.60 Quick RatioN/APrice-To-Earnings Trailing P/E Ratio-2.25 Forward P/E Ratio-2.39 P/E GrowthN/A Sales & Book Value Annual Sales$13.45 million Price / Sales33.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book2.57Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees244 Outstanding Shares59,437,000Market Cap$449.94 million OptionableOptionable DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions What is DBV TECHNOLOGIE/S's stock symbol? DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT." How were DBV TECHNOLOGIE/S's earnings last quarter? DBV TECHNOLOGIE/S (NASDAQ:DBVT) issued its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History. When is DBV TECHNOLOGIE/S's next earnings date? DBV TECHNOLOGIE/S is scheduled to release their next quarterly earnings announcement on Friday, March 15th 2019. View Earnings Estimates for DBV TECHNOLOGIE/S. What price target have analysts set for DBVT? 9 brokers have issued 12-month price targets for DBV TECHNOLOGIE/S's shares. Their predictions range from $5.25 to $33.00. On average, they expect DBV TECHNOLOGIE/S's share price to reach $17.7813 in the next twelve months. This suggests a possible upside of 134.9% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S. What is the consensus analysts' recommendation for DBV TECHNOLOGIE/S? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DBV TECHNOLOGIE/S. Has DBV TECHNOLOGIE/S been receiving favorable news coverage? Media coverage about DBVT stock has trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. DBV TECHNOLOGIE/S earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Are investors shorting DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,601,337 shares, a drop of 35.4% from the January 15th total of 2,479,569 shares. Based on an average daily trading volume, of 280,908 shares, the short-interest ratio is presently 5.7 days. View DBV TECHNOLOGIE/S's Current Options Chain. Who are some of DBV TECHNOLOGIE/S's key competitors? Some companies that are related to DBV TECHNOLOGIE/S include Crispr Therapeutics (CRSP), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Coherus Biosciences (CHRS), Editas Medicine (EDIT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Vericel (VCEL) and Novavax (NVAX). Who are DBV TECHNOLOGIE/S's key executives? DBV TECHNOLOGIE/S's management team includes the folowing people: Dr. Pierre-Henri Benhamou, Co-Founder & Non-Exec. Chairman (Age 64)Mr. David Schilansky, Deputy CEO & CFO (Age 44)Dr. Laurent Martin, Chief Devel. Officer (Age 52)Mr. Daniel Tassé, Chief Exec. Officer (Age 59)Mr. Bertrand Dupont, Co-Founder & CTO (Age 67) Who are DBV TECHNOLOGIE/S's major shareholders? DBV TECHNOLOGIE/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (2.77%), First Midwest Bank Trust Division (1.66%), Perceptive Advisors LLC (1.39%), Jennison Associates LLC (0.90%), BlackRock Inc. (0.51%) and Premier Asset Management LLC (0.29%). Which major investors are selling DBV TECHNOLOGIE/S stock? DBVT stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Jennison Associates LLC, BlackRock Inc. and Geode Capital Management LLC. Which major investors are buying DBV TECHNOLOGIE/S stock? DBVT stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, First Midwest Bank Trust Division, Premier Asset Management LLC, OLD Mission Capital LLC and Exane Asset Management. How do I buy shares of DBV TECHNOLOGIE/S? Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is DBV TECHNOLOGIE/S's stock price today? One share of DBVT stock can currently be purchased for approximately $7.57. How big of a company is DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S has a market capitalization of $449.94 million and generates $13.45 million in revenue each year. The company earns $-166,930,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe. What is DBV TECHNOLOGIE/S's official website? The official website for DBV TECHNOLOGIE/S is http://www.dbv-technologies.com. How can I contact DBV TECHNOLOGIE/S? DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected] MarketBeat Community Rating for DBV TECHNOLOGIE/S (NASDAQ DBVT)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 272 (Vote Outperform)Underperform Votes: 284 (Vote Underperform)Total Votes: 556MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2019 by MarketBeat.com StaffFeatured Article: How is Preferred Stock Different from Common Stock?